Patrick Lundgren

Patrick Lundgren is an investor and biotech incubation lead at Hummingbird Ventures, based in Boston, Massachusetts.1 He has an extensive background in biotech, immunology, and venture capital.

Education and Academic Achievements

Patrick holds impressive academic credentials:

• PhD in Immunology from the University of Pennsylvania
• MSc in Integrated Immunology from the University of Oxford (graduated with Distinction)
• BA (Hons) in Natural Sciences from the University of Cambridge1

During his PhD, Patrick published over 10 papers in prestigious journals such as Cell, Nature, and Nature Metabolism.1 His research covered topics including adipocyte biology, immunology, and gut-brain signaling.

Professional Experience

Patrick's career spans various roles in biotech and venture capital:

• Current Role: Investor at Hummingbird Ventures
• Associate at Flagship Pioneering (August 2022 - Present)
• Flagship Pioneering Fellow (June 2021 - August 2021)
• Venture Fellow at Pear VC (2020 - 2021)
• Co-Founder of NanoXCell Therapeutics (2018 - 2020)1

At Flagship Pioneering, he is involved in originating and building bioplatform companies.1 His experience at Pear VC included sourcing and analyzing startups in the biotech sector.

Entrepreneurial Ventures

As a co-founder of NanoXCell Therapeutics, Patrick worked on developing a non-viral nanotechnology platform aimed at creating single-cell CAR T cell therapies.1 This venture was backed by the University of Pennsylvania, National Science Foundation, and Johnson & Johnson.

Additional Information

Patrick is bilingual, with native or bilingual proficiency in both Swedish and English.1 His diverse background, which includes a summer research fellowship at NASA's Jet Propulsion Laboratory, demonstrates his multidisciplinary approach to science and innovation.